

SEP. 19 SAT.

ROOM 701BC

Time	Topic	Speaker	Moderator
08:00-08:20	Registration		
08:20-08:30	Opening Remarks	Yen-Shen Lu Fang-Ming Chen	
Distinguished Pioneer Lecture			
08:30-09:00	From Aromatase Biology to Single-Cell/Spatial Transcriptomics Analysis: A Lifetime's Journey in Precision Oncology of Breast Cancer.	Shiuan Chen	King-Jen Chang
Session (1) Bridging Global Evidence and Regional Practice			
09:00-09:30	From Evidence to Consensus: The Evolution and Global Impact of the NCCN Breast Cancer Guidelines: A Perspective from the Founding Chair of the NCCN Guidelines Panel for Breast Cancer	William J Gradishar	Ming-Feng Hou
09:30-10:00	From Global to Local: Ethnic and Geographic Impact in the Treatment of Breast Cancer Patient	Shigehira Saji	Jyh-Cherng Yu
10:00-10:40	Translating ctDNA Dynamics into Clinical Strategy: Innovation of Next-Generation SERD in 1L HR+/HER2- mBC	François-Clément Bidard	Ling-Ming Tseng
10:40-11:00	Coffee Break		
11:00-11:40	The Sustainable Efficacy of CDK4/6 Inhibitor Therapy in HR+/HER2- Node+ High-Risk Early Breast Cancer	Marc Thill	Ta-Chung Chao
11:40-12:10	Impact and Pitfall of International Guideline and <u>Real World</u> Practice	William J Gradishar Shigehira Saji François-Clément Bidard Marc Thill Chiun-Sheng Huang	Yen-Shen Lu Fang-Ming Chen
Luncheon Symposium (1)			
12:10-12:55	Treatment Landscape for HR+/HER2- mBC with PIK3CA Pathway Mutations	Erica L. Mayer	Yen-Shen Lu
12:55-13:10	Coffee Break		
Session (2) Optimizing Treatment Strategies in Breast Cancer			
13:10-13:50	Redefining the Therapeutic Role of TKIs in HER2-Positive Metastatic Breast Cancer	Virginia Borges	Fiona Tsui-Fen Cheng
13:50-14:30	Redefining First-Line Treatment in HER2+ mBC: Insights from DESTINY-Breast09	Wei-Wu Chen	Shin-Cheh Chen
14:30-15:10	Defining the Optimal Sequence in HER2+ MBC: Balancing Category 1 Evidence with Emerging Frontline Data	Chi-Feng Chung	Ming-Shen Dai
15:10-15:30	Coffee Break		
15:30-16:10	Longer Survival and Better Quality of Life: Two Endpoints to Be Considered in Metastatic HER2-Positive MBC	Joohyuk Sohn	Ching-Hung Lin
16:10-16:50	Improving Outcomes: Redefining High Risk and Care in HR+/HER2- Early Breast Cancer	Dejan Juric	Hsien-Tang Yeh
16:50-17:20	From Immune Infiltration to Immune Intervention: The Changing Landscape of Breast Cancer Immunotherapy	Sherene Loi	Shyr-Ming Sheen-Chen
17:20-18:00	Addressing Unmet Needs in TNBC: The Evolving Role of ADC Therapies	Ching-Hung Lin	Tsu-Yi Chao

SEP. 20 SUN.

ROOM 701BC

Time	Topic	Speaker	Moderator
Breakfast Symposium			
08:10-08:50	Beyond the Fatigue Score: Immune Cell Profiling, Cytokine Signatures, and Inflammatory Correlates of PG2 in Breast Cancer	Chun-Yu Liu Ming-Han Yang	Kun-Ming Rau
Session (3) From Precision to De-escalation: Redefining the Role of Surgery in Breast Cancer			
08:50-09:20	AI in BC Care: Translating AI into Precision Medicine	Serene Goh	Chi-Cheng Huang
09:20-09:50	Surgical De-escalation After Neoadjuvant Therapy: When Less Is More	Susan Boolbol	Chen-Hsiang Chang
09:50-10:10	Coffee Break		
10:10-10:40	Cryoablation for Breast Cancer: 2026 Update	Michael Berry	Yao-Jen Chang
10:40-11:10	Robotic Nipple-Sparing Mastectomy: Technique, Outcomes, and Future Directions	Antonio Toesca	Guo-Shiou Liao
11:10-11:30	Discussion		ALL
Session (4) Optimizing Long-Term Outcomes in Breast Cancer: From Evidence to Real-World Practice			
11:30-12:10	Advancing the Management of ER+ HER2- mBC: Integrating Evidence and Experience	Adam M. Brufsky	Liang-Chih Liu
Luncheon Symposium (2)			
12:10-12:55	One Step Further: Tackling the Unmet Needs to Reduce Recurrence Risk in HER2+ Breast Cancer	Chin-Yao Lin	Dar-Ren Chen
12:55-13:10	Coffee Break		
Session (5) Advancing Breast Cancer Treatment Through Innovative Therapeutic Strategies			
13:10-13:50	Emerging ADC Treatment Strategies in Metastatic HR+/HER2- Breast Cancer	Kim Min-Hwan	Hsien-Kun Chang
13:50-14:30	Evolving Treatment Landscape in HER2-Positive Early Breast Cancer: The Integration of ADC Therapies	Sibylle Loibl	Chiun-Sheng Huang
14:30-14:45	Coffee Break		
14:45-15:25	Solo or Duet - Elevating Outcomes for Patients Starting 1L mTNBC Therapy by Anti-Trop2 ADC	Dwan-Ying Chang	Shou-Tung Chen
15:25-15:45	Clinical experience with S-1 in Japan: evidence and practical integration in early breast cancer	Masahiro Takada	Yuan-Ching Chang
15:45-16:05	Practical Insights on Using TS-1 as Adjuvant Therapy in HR+/HER2- Early Breast Cancer: Cases, Tolerability, and Results	Li-Kun Ko	
16:05-16:35	Disease Progression Under ADC, What Would We Do? Now and Future	Naoto T. Ueno	Wen-Hung Kuo
16:35-16:45	Award Ceremony		Yen-Shen Lu Fang-Ming Chen
16:45-17:00	Closing		

SEP. 19 SAT.

ROOM 701D

TBCS-GBCC -JBCS-SSO Joint Session: Less, But Better: The New Standard of Breast Surgery

Time	Topic	Speaker	Moderator
09:30-09:50	De-escalation of Breast Surgery: Who Can Safely Receive Less?	Chin-Sheng Hung	Kuo-Ting Lee Jun Won Min
09:50-10:10	Can Axillary Surgery Be Safely Omitted After Neoadjuvant Therapy?	Laura Dominici	
10:10-10:30	Breast Surgery in Young and High-Risk Patients: Where Is the Limit of De-escalation?	Han-Byoel Lee	
10:30-10:50	Is There Still a Role for Surgery in De Novo Stage IV Breast Cancer?	Sung Gwe Ahn	Ming-Yang Wang Yutaka Yamamoto
10:50-11:10	Precision Breast Surgery in Japan: Toward Surgical De-escalation After Systemic Therapy	Hideo Shigematsu	
11:10-11:30	Setting the Future Standard of Breast Surgery: The SSO Perspective	Mediget Teshome	
11:30-12:00	Discussion	ALL	

Luncheon Symposium

12:00-12:40	Treatment Landscape Shift in 2L+ HR+/HER2- mBC: ESR1 mutation and oral SERD	Jason Aboudi Mouabbi	Jiun-I Lai
-------------	---	-------------------------	------------

SEP. 19 SAT.

ROOM 701D

Young Doctors Forum & Young Doctors Debate From Evidence to Impact: How Young Surgeons Shape the Future

Time	Topic	Speaker	Moderator
Young Doctors Forum (YDF)			
14:00-14:05	Opening	Chi-Cheng Huang	
14:05-14:30	From Trials to Practice: Interpreting Global Evidence in Modern Breast Cancer Care	Marc Thill	
14:30-14:55	Beyond the Guidelines: Clinical Decision-Making in Modern Axillary Management	Laura Dominici	
14:55-15:00	Q&A	ALL	
15:00-15:05	Coffee Break		

Young Doctors Debate (YDD)

15:05-15:45	"No Scar, No Axilla?" Can Axillary Surgery Be Completely Omitted in Initially cN0 HER2-Positive Breast Cancer Patients Achieving Radiologic and Pathological Complete Response in the Breast After Neoadjuvant Systemic Therapy?	YDF Invitees	Chiao Lo
15:45-16:25	Pull the Trigger or Stay the Course? Should Endocrine Therapy Be Preemptively Switched Based Solely on Plasma ESR1 Mutation Detection via ctDNA Before Radiologic Progression in HR+/HER2- Advanced Breast Cancer?		Wei-Wu Chen
16:25-16:30	QA & Closing	Jeong Eon Lee	
16:30-16:50	Group Photo	ALL	

Special Lecture

17:10-17:50	The World's First NGS-Based Prognostic Assay and Real-World Clinical Experience in Korea	Wonshik Han	Chiun-Sheng Huang
-------------	--	-------------	-------------------

SEP. 19 SAT.

ROOM 701A

Oral Presentation

Time	Topic	Presenter
10:30-10:40	1 CDH1-Loss Driven Unfolded Protein Response (UPR) Suppression and Transcriptomic-Proteomic Discordance in mTOR-AKT Axis Define Therapeutic Vulnerabilities in Invasive Lobular Carcinoma	Wen-Ying Lin
10:40-10:50	2 Pre-treatment tumor microenvironment profiling identifies resting mast cells as a predictor of resistance to neoadjuvant pembrolizumab-based therapy in triple-negative breast cancer	Chi-Cheng Huang
10:50-11:00	3 Proportion of Endocrine Insensitivity After CDK4/6 Inhibitors Across Endocrine Therapy Based Regimens: A Secondary Analysis Using Reconstructed Individual Patient Data	Shang-Hsuan Peng
11:00-11:10	4 Impact of Undertreatment on Survival in Elderly Breast Cancer: A Nationwide Population-Based Cohort	Jun-Hee Lee
11:10-11:20	5 Comparative Genomic Profiling of Circulating Tumor DNA and Tissue DNA Reveals Complementary Genomic Information in Japanese Patients with Metastatic Breast Cancer	Yuri Fujimoto
11:20-11:30	6 PG2-Associated Immune Priming Enhances Checkpoint Inhibitor Activity: Integrated Clinical Absolute Lymphocyte Count Dynamics and Preclinical Validation in Breast Cancer Models	Ming-Shen Dai
11:30-11:40	7 Residual ductal carcinoma in situ and axillary nodal disease after neoadjuvant chemotherapy: A subtype-specific analysis in human epidermal growth factor receptor 2-positive and triple-negative breast cancer	Chihoon Lee
11:40-11:50	8 Clinicopathologic characteristics of Asian American breast cancer patients by ethnic and geographic subgroup: A 12-year single-institution experience	Andrew Seto
11:50-12:00	9 Carry-Over Effect of Immune Checkpoint Inhibitors on Overall Survival in Patients with Advanced Cancers: A Systematic Review and Meta-Regression Analysis	Shang-Hsuan Peng
12:00-12:10	10 Validation of the ASTRRA-derived Composite Risk Model for Ovarian Function Suppression Benefit in Premenopausal HR-Positive Breast Cancer	Dahn Byun
12:10-13:10	Lunch Time	
13:10-13:20	11 False Estradiol Elevation During Abemaciclib Therapy: Clinical and Ex Vivo Evidence of Platform-Specific Immunoassay Interference	Hsing-Wu Chen
13:20-13:30	12 SGLT2 inhibitors and risk of distant metastasis in breast cancer patients with type 2 diabetes: A target trial emulation with biological plausibility analysis	Cho-Hao Lee
13:30-13:40	13 SHMT2 Couples One-Carbon Metabolism to Redox Homeostasis to Drive Triple Negative Breast Cancer (TNBC) Metastasis	Yen-Dun Tzeng
13:40-13:50	14 Trends of Breast Cancer Incidence, and Mortality by County-Level Income Disparities from 2000 to 2021	Min Kyoon Kim
13:50-14:00	15 Sole Intraoperative Radiotherapy (IORT) versus External Beam Radiotherapy (EBRT) for Early-Stage Breast Cancer: A Nationwide Cohort Study Using the Taiwan National Health Insurance Research Database	Yu-Chen Hsu
14:00-14:10	16 Pharmacogenomic Repurposing of Cardiac Glycosides Against the ATP Synthasome in Metastatic Breast Cancer	Chia-Jung Li
14:10-14:20	17 Next Generation Estrogen Receptor Degradors in Patients with Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer with Endocrine Resistance: A Systematic Review, and Meta-Analysis	Tzu-Tung Kan
14:20-14:30	18 A propensity score-adjusted real-world comparison of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer: A Taiwanese multicenter cohort study	Tsung-Han Wu
14:30-14:40	19 Characteristics of the Tumor Immune Microenvironment in Residual Triple-Negative Breast Cancer After Neoadjuvant Therapy	Yumiko Akita
14:40-15:00	Coffee Break	
15:00-15:10	20 Revisiting adjuvant chemotherapy in premenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: real-world evidence from an Asian cohort	Jen-Yu Chuang
15:10-15:20	21 Minnelide Reprograms Multidrug-Resistant Breast Cancer Through the miR-6838- 5p/CARMA3/Ferroptosis Defense Axis	Tung-Wei Hsu
15:20-15:30	22 Real-world efficacy and safety of TS-1 plus endocrine therapy in hormone receptor-positive, HER2- negative early-stage breast cancer: A multicenter Taiwanese experience including NATALEE-eligible population.	Ching-Ting Wei
15:30-15:40	23 ILCness unmasks hidden lobular-like states within ductal breast cancer	Masanori Oshi
15:40-15:50	24 Luteolin-7-O-glucoside suppresses hormone receptor-positive breast cancer progression and metastasis through the K63-linked polyubiquitinated USP7-H3K56ac-PLK1 axis	Joseph Lin
15:50-16:00	25 Current Status of Breast Reconstruction After Mastectomy and the Risk of Postoperative Complications by Timing of Reconstruction: A Nationwide Population-Based Cohort Study in Korea	So-Youn Jung

SEP. 19 SAT.

ROOM 701A

After Breast Cancer: Nursing Care from Body Image to Intimacy

Time	Topic	Speaker	Moderator
16:30-17:05	Beyond Physical Recovery: Body Image, Dyadic Interaction, and Intimacy in Breast Cancer Survivorship Care	Su-Ying Fang	Hsiu-Ling Chou
17:05-17:40	Beyond the Body: Reclaiming Who I Am -Psychological Healing and Readiness for Intimacy After Breast Cancer	Szu-Ling Chiu	Kun-Ming Rau
17:40-18:00	Discussion	Su-Ying Fang Szu-Ling Chiu	Hsiu-Ling Chou Kun-Ming Rau

SEP. 19 SAT.

ROOM 702

Let's Meet the Master

Time	Speaker	Moderator
11:10-11:50	① Let's Meet the Master (1) Dejan Juric	Hsu-Huan Chou
12:20-13:00	② Let's Meet the Master (2) Antonio Toesca	Wen-Ling Kuo
13:30-14:10	③ Let's Meet the Master (3) William J Gradishar	Chun-Yu Liu
14:40-15:20	④ Let's Meet the Master (4) François-Clément Bidard	I-Chun Chen

SEP. 20^{SUN.}

ROOM 701A

Mini-Symposium

Time	Topic	Speaker	Moderator
10:10 -10:50	Evolving paradigms in HR+/HER2- eBC: The rise of next-generation oSERD	Hsu-Huan Chou	Wen-Ling Kuo
10:50-11:30	Real World Experience of Eribulin for Metastatic Breast Cancer	Cheng-Wei Chou	Shih-Che Shen
11:30-12:10	Effectiveness of CDK4/6 inhibitor treatment for HR+/HER2- meta-static breast cancer	Marc Thill	Chao-Ming Hung

Luncheon Symposium

12:10-12:50	From Access to Better Outcomes-The New Era of Early HER2-Positive Breast Cancer Care in Taiwan	Chih-Hao Huang	Hsien-Tang Yeh
-------------	--	----------------	----------------

Robotic Surgery Special Session

12:50-13:00	Opening Global Approval Status of da Vinci Robotics in Breast Surgery	Micheal P. Berry	
13:00-13:25	Pioneering Robotic Mastectomy with Insightful Perspectives	Antonio Toesca	Micheal P. Berry
13:25-13:50	Learning Pathways and Training Models of Robotic Surgery	Tristen Park	Han-Byoel Lee
13:50-14:15	Elements that Constitute Successful Robotic Breast Surgical Practice	Wen-Ling Kuo	Ling-Ming Tseng
14:15-14:40	Reconstruction after Robotic Mastectomy	Alice Yao	Fiona Tsui-Fen Cheng
14:40-15:00	Panel Discussion	All Speakers and Moderators	Wen-Ling Kuo

SEP. 20^{SUN.}

ROOM 701A

Functional Recovery and Physical Therapy After Breast Cancer Surgery

Time	Topic	Speaker	Moderator
15:10-15:50	From Surgical Success to Functional Recovery: Evidence-Based Physical Therapy in Comprehensive Breast Cancer Care and a Clinical Case	Wendy TJ Wang Yi Cheng Lin	Ming-Feng Hou